Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > necitumumab
necitumumab
Friday 15 April 2016
| WP |
Necitumumab (proposed INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).
The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).